Open Access Research article

Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

Marc G Vervloet1*, Arjan D van Zuilen2, Annemieke C Heijboer3, Piet M ter Wee1, Michiel L Bots4, Peter J Blankestijn2, Jack FM Wetzels5 and MASTERPLAN group study

Author Affiliations

1 Department of Nephrology and ICaR-VU, VU university medical centre, Amsterdam, The Netherlands

2 Department of Nephrology, UMCU, Utrecht, The Netherlands

3 Department of Clinical Chemistry, VU university medical centre, Amsterdam, The Netherlands

4 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

5 Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

For all author emails, please log on.

BMC Nephrology 2012, 13:20  doi:10.1186/1471-2369-13-20

Published: 24 April 2012



Fibroblast growth factor 23 (FGF23) has emerged as a risk factor for cardiovascular disease and mortality throughout all stages of chronic kidney disease (CKD), independent from established risk factors and markers of mineral homeostasis. The relation of FGF23 with other renal and non-renal cardiovascular risk factors is not well established.


Using stored samples, plasma FGF23 was determined in 604 patients with moderate to severe kidney disease that participated in the MASTERPLAN study (ISRCTN73187232). The association of FGF23 with demographic and clinical parameters was evaluated using multivariable regression models.


Mean age in the study population was 60 years and eGFR was 37 (± 14) ml/min/1.73 m2. Median proteinuria was 0.3 g/24 hours [IQR 0.1-0.9]. FGF23 level was 116 RU/ml [67-203] median and IQR. Using multivariable analysis the natural logarithm of FGF23 was positively associated with history of cardiovascular disease (B = 0.224 RU/ml; p = 0.002), presence of diabetes (B = 0.159 RU/ml; p = 0.035), smoking (B = 0.313 RU/ml; p < 0.001), phosphate level (B = 0.297 per mmol/l; p = 0.0024), lnPTH (B = 0.244 per pmol/l; p < 0.001) and proteinuria (B = 0.064 per gram/24 hrs; p = 0.002) and negatively associated with eGFR (B = -0.022 per ml/min/1.73 m2; p < 0.001).


Our study demonstrates that in patients with CKD, FGF23 is related to proteinuria and smoking. We confirm the relation between FGF23 and other cardiovascular risk factors.

Cardiovascular disease; CKD; FGF23; Phosphate; Proteinuria; Smoking